A Double-blind, Placebo Controlled, Randomized, Phase IIa Study to Assess the Safety, Tolerability, Efficacy, and Pharmacokinetics of Repeated Topical Applications Over 42 Days of AP611074 5% Gel in Condyloma Patients
The purpose of this study is to determine the safety, tolerability and efficacy of the topical application of AP611074 5% gel during 6 weeks on ano-genital warts caused by human papillomavirus (HPV).
100 Clinical Results associated with Anaconda Pharma SASU
0 Patents (Medical) associated with Anaconda Pharma SASU
100 Deals associated with Anaconda Pharma SASU
100 Translational Medicine associated with Anaconda Pharma SASU